Aptevo Therapeutics Inc. (APVO) Reports 79% Remission Rate in TP53-Mutated AML

Aptevo Therapeutics reported a 79% remission rate in TP53-mutated AML patients treated with mipletamig, exceeding a 41% benchmark. 10 of 47 patients proceeded to stem cell transplantation. The results are from an early clinical trial, with further data needed to assess impact.

Original reporting
Published Nov 16, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 1:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Aptevo Therapeutics Inc. (APVO) Reports 79% Remission Rate in TP53-Mutated AML — source image
Decision brief

The 30-second read

$APVOBullishMed
01

Why it matters

The 79% remission figure is substantially above the historical 41% benchmark, suggesting a potentially differentiated therapy.

02

Market read

First‑time release of strong AML trial data; likely short‑term price move for APVO.

03

What to watch

Trial size is small (47 patients) and results are interim; regulatory path and commercial rollout remain uncertain.

Relevance 8/10Novelty 8/10Timing: today

Background

Aptevo Therapeutics (NASDAQ:APVO) is a clinical‑stage biotech developing mipletamig for acute myeloid leukemia.

Company-level read

Ticker impact

$APVOBullishHigh confidence
Context

Aptevo disclosed a 79% CR/CRi remission rate in TP53‑mutated AML and 10 of 47 patients proceeding to stem‑cell transplant.

Expected impact

likely upward pressure as investors price in the high remission rate

Evidence & confidence

First‑time disclosure of compelling trial results for a clinical‑stage biotech typically triggers a short‑term rally.

Market effects

Positive data may boost sentiment in the broader AML/oncology biotech space.

Limited to U.S. biotech investors; no broader regional effect.

Minimal; relevance confined to specialty biotech investors.

Counterpoint

Data is early‑stage; efficacy may not translate to later phases, so caution is warranted.

Key entities

  • Aptevo Therapeutics Inc.

    Developer of mipletamig, reporting early trial data.

Related articles

$APVOHighAI 8/10

Aptevo reports Q3 results, mipletamig AML trial data

Aptevo Therapeutics (APVO) reported a Q3 2026 net loss of $6.5M, down from $7.5M in Q3 2025. Cash reserves fell to $8.3M. The company shared positive clinical data for mipletamig in AML treatment, with 79% remission rate in a small trial. It aims to complete Phase 1b trials by year-end and plans regulatory interaction in early 2027. Aptevo raised $4.5M in August via warrant inducement and private placement.

$APVOHighAI 8/10

Aptevo 3Q 2026: EPS ($5.19) — 10-Q Summary

Aptevo reported a wider net loss for 3Q 2026, driven by a $2.8M deemed dividend and lower expenses. EPS loss narrowed to $5.19 vs. $40.13 YoY. Clinical progress includes 79% CR/CRi rate in AML patients and Phase 1b completion targeted for 2026. APVO451 received a $1.5M grant for IND-enabling studies.

$APVOMedAI 8/10

Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibits 99.1 Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results Mipletamig achieves 79% remission rate in high-risk TP53-mutated AML, nearly double the published historical benchmark Ten of 47 patients re

$APVOMedAI 8/10

Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors

Aptevo Therapeutics Inc. (APVO) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Aptevo Presents Preclinical Data at SITC 2026 Showing Potential to Overcome Immune Suppression in Solid Tumors In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity—offering potential for difficult-